ASAlexander Schmittel

Alexander Schmittel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander Schmittel has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Incidence and initial characterization of circulating tumor cells in different cancer entities.

    by Z. Liu, A. Fusi, I. Tinhofer, A. H. Schmittel, U. Keilholz

    E21083 Background: Circulating tumor cell (CTC) quantification has been approved for monitoring of blood from metastatic breast, colon and prostatic cancer patients. In other cancers little is known about the presence of CTCs. CTCs might represent a potential alternative to invasive biopsies and assessment of their receptor profile may be helpful in planning and monitoring treatment strategies. This study was undertaken to investigate prevalence and characteristics of CTCs in a variety of solid tumors. Methods: After informed consent, fifty consecutive 20 mL-peripheral blood samples were collected from 38 patients with different metastatic epithelial cancers (n = 30) or metastatic melanoma (n = 8). After lysis of erythrocytes, cells were enriched for tumor cells by CD45 depletion. Cells were stained for CD45 to exclude leukocytes from the analysis and for the epithelial markers EpCAM and Cytokeratin 7, 8 or the melanoma marker HMW-MAA/MCSP, respectively. In 16 samples from patients affected by epithelial cancers a co-staining for EGFR was carried out. Control tubes including appropriate isotypic controls were added. Cells were analysed on a FACSCanto II. CTCs were defined EpCAM+Cytokeratin+CD45- in case of epithelial cancers or as HMW-MAA/MCSP+CD45- in case of melanoma. Results: In blood from patients with epithelial cancers CTCs were detected in 20/40 samples (50%). The absolute number of CTCs ranged from 2 to 37 (median 3) per 10 mL of blood. Besides breast cancer (5/9) and colon cancer (3/11) samples, CTCs were also detected in ovarian (4/8), cervix (2/4), head and neck (3/3), gastric (2/3) and non-small cell lung cancer (1/2) samples. In ten out of 16 samples (62.5%) CTCs were positive for EGFR (4 breast cancer, 2 head and neck, 2 ovarian, 1 gastric and 1 cervix cancer sample). In blood from melanoma patients CTCs were detected in 6/10 samples (60%). The absolute number of CTCs ranged from 5 to 551 (median 19) per 10 mL of blood. Conclusions: CTCs can often be detected in blood from patients with metastatic epithelial cancer or melanoma. CTCs were more abundant in melanoma compared to epithelial cancers. Phenotypic characterization identified EGFR as potential target to eradicate the EGFR-positive pool of CTCs. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck Serono Merck Serono Merck Serono

  • Brain metastases in non-small cell lung cancer patients at the time of first diagnosis: Therapy and outcome.

    by A. H. Schmittel, S. H. Hoecht, K. Schiemenz, W. Hinkelbein, E. Thiel, U. Keilholz

    E18114 Background: Brain metastases frequently occur in non-small cell lung cancer (NSCLC). Most clinical trials in stage IV NSCLC have excluded patients with brain metastases therefore the outcome of this patient population remains unclear. We retrospectively analysed treatment and outcome of patients with brain metastases at the time of first diagnosis and descriptively investigated the outcome after resection and the role of systemic chemotherapy in addition to whole brain radiotherapy (WB-RT). Methods: All patients diagnosed and treated in the department of radiooncology between 2001 and 2006 were included into the analysis. Patients and disease characteristics, treatment, outcome and data on the systemic therapy were taken from the patient's charts and by contacting the general physicians. Results: Sixty-six patients with a median age of 59 years (range 38-80) were identified. Thirty-two (48%) were female, 7 were never-smokers, 22 (33%) had a Karnofsky performance status (KPS) of ≥ 70% and the majority of 54 (82%) had adenocarcinomas. Ten (15%) had a single brain metastasis, 6 (9%) had asymptomatic brain metastases. In ten of 66 (15%) metastases were resected (n = 10), all patients received WB-RT with a dose of 30 Gy given in 10 fractions. Fourty-one (62%) in addition received systemic chemotherapy. Median survival of the entire population was 7 months (95% CI 4.8-9.2). Univariate analysis revealed a significantly improved median survival for patients with resected brain metastases 19 (95% CI 1.8-36.2) versus 5 months (95% CI 2.9-7.1) (p < 0.01). Patients with a KPS ≥ 70% had a median survival of 9 (95% CI 5.0-13.0) versus 3 months (95% CI 0.7-5.3) in KPS < 70% patients (p = 0.005). Survival analysis did not show differences between genders, histology and patients receiving chemotherapy versus no chemotherapy. Conclusions: This analysis confirms earlier studies showing an improved survival for patients after resection of brain metastases and in patients with good performance status. This retrospective analysis failed to demonstrate a benefit from systemic chemotherapy and therefore is the basis for a prospective trial on chemotherapy in patients with brain metastases at the time of first diagnosis. No significant financial relationships to disclose.

  • Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer

    by M. Knoedler, T. C. Gauler, A. Matzdorff, A. Dietz, V. Gruenwald, D. Arnold, B. Hennemann, M. Schroeder, C. Hofele, A. Schmittel, et al.

    6066 Background: Treatment options for patients with squamous cell cancer of the head and neck (SCCHN) are limited. Cetuximab, an antiepidermal growth factor receptor monoclonal antibody, and taxanes have already been used and shown clinical activity in this indication. This study assessed the efficacy and safety of cetuximab administered in combination with docetaxel in patients with Stage IIII/IV recurrent and/or metastatic SCCHN who failed on platinum-based therapy. Methods: Patients with relapse or progression after platinum therapy received cetuximab (initial dose of 400 mg/m2, followed by subsequent weekly doses of 250 mg/m2 until disease progression) and docetaxel (35 mg/m2 on days 1, 8, 15 of a 4-week cycle for a maximum of 6 cycles). The primary endpoint was the objective response rate (after cycle 2, 4, 6) according to RECIST criteria. Secondary endpoints included toxicity, time to progression and quality of life. Results: 47 patients with a median age of 59 years were enrolled within seven months across ten German sites. 45 patients were evaluable. Partial responses have been achieved in 9 (20%) patients and stable disease in 12 (27%) patients for an overall disease control rate (partial response and stable disease) of 47%. Treatment was generally tolerated without evidential overlapping toxicities. Major grade III/IV toxicities included gastric perforation (n= 1), pneumonia (n= 5), mucositis (n= 4) and skin toxicities (n= 9). Conclusions: The combination of cetuximab and docetaxel demonstrated clinically relevant efficacy in platinum-pretreated patients with SCCHN. No significant financial relationships to disclose.


  • Efficacy of transarterial chemoembolization (TACE) of liver metastases from uveal melanoma

    by R. Schuster, M. Lindner, F. Wacker, M. Krössin, N. E. Bechrakis, M. H. Foerster, E. Thiel, U. Keilholz, A. Schmittel

    20013 Background: The liver is the predominant site of metastases in the majority of patients with uveal melanoma. Response rates to systemic chemotherapy are low and median survival is very short with 6–9 months. Locoregionary treatment like transarterial chemoembolisation (TACE) is of interest especially in patients in whom the liver is the only site of disease or disease progression after systemic chemotherapy. We therefore report on our experience with TACE in metastatic uveal melanoma. Methods: All patients with documented disease progression in the liver treated with TACE between 2003 and 2007 at our institution were analysed. TACE of liver metastases was performed by interventionally placing a catheter into the hepatic artery followed by the administration of sherex (900mg) and either fotemustin (100mg/m2) or cisplatin (50mg, n=4). The treatment was repeated after a minimum of 2 weeks and terminated in case of disease progression or severe toxicity. Results: 21 patients received a median of 2 TACE (range 1 to 8). Median age was 52 years (range 24 - 80). Median time between diagnosis of metastases and TACE was 10 month (range 1 to 24). All but one patient had prior systemic chemo- or immuno-therapy (median number of prior therapies: 1.5; range 0 to 3). Grade III toxicity consisted of nausea (n=1), fever of unknown cause (n=1), a splenic infarction (n=1), thrombocytopenia (n=1), and a gastric ulcer (n=1). No grade IV toxicity or catheter associated complications were observed. 12 of 21 patients had stable disease for at least 2 month, one a partial, and one a complete remission. The median time to progression (TTP) was 4 months (95% CI: 3–5 month) and the median overall survival (OS) was 5 month (95% CI: 4–6 month). Both TTP and OS where significantly shorter in case of pre-treatment lactate dehydrogenase (LDH) above the twofold upper limit of normal (n=11): TTP 2 versus 5 month (p=0.001) and OS 5 versus 6 months (p=0.026). Conclusions: TACE is well tolerated in patients with liver metastases from uveal melanoma. Although the majority of patients were pretreated with systemic chemotherapy objective remission could be observed. TACE should further be evaluated as first line therapy in prospective studies. No significant financial relationships to disclose.

  • Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma

    by P. M. Deckert, J. M. Siehl, E. Thiel, A. Schmittel, G. Hütter, H. Szelényi, U. Keilholz

    9011 Background: Anthracycline/ifosfamide combination is the most effective chemotherapy in soft tissue sarcoma. To improve tolerability and potentially efficacy of this combination we combined liposomal daunorubicin (L-Dauno) with high dose continuous infusion ifosfamide. Methods: In a single-arm phase II study 40 patients were enrolled with a median age of 57 years (19 to 78 years). Treatment regimen was L-Dauno 100 mg/m2 and ifosfamide 5 g/m2 over 24 h every 4 weeks with G-CSF support. Initially, 5 patients were included after failure of a doxorubicin/ifosfamide regimen, but none of these responded. Subsequently, 35 patients were treated first line. Results: A total of 115 cycles (range 1 to 7) were given. Toxicity was tolerable with 5 episodes (4,8 % of cycles) of ifosfamide related CNS toxicity grade II and 9 episodes (8,6 % of cycles) of neutropenic fever. Treatment had to be terminated due to a pseudo-allergic reaction to L-Dauno in one patient. One patient had ifosfamide related acute renal failure and was further treated with L-Dauno alone. No other non-hematological toxicity exceeding grade II was observed. Eleven (31,4 %) out of 35 patients without pretreatment achieved a PR, all after 2 treatment cycles, 6 patients (17,1 %) had stable disease and 12 patients (34,3 %) progressed; 6 patient were not evaluable (2 treatment unrelated early deaths, 2 lost to follow up, 1 adjuvant treatment, 1 to early to evaluate). Median time to progression was 10 months, median overall survival 16 months. PR with respect to histology was: 4/7 PNET, 1/6 leiomyosarcoma, 2/4 liposarcoma, 1/2 synovial sarcoma, 1/3 pleomorphic sarcoma, 1/1 malignant histiocytoma and 1/2 carcinosarcoma. Four of the responding patients received a consolidating high-dose-chemotherapy with subsequent stem cell support. Conclusions: IDx is a well tolerated and highly active chemotherapy regimen for first line treatment of soft tissue sarcoma, even in elderly patients. Randomized studies with this regimen are warranted. No significant financial relationships to disclose.

  • A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high-grade non-Hodgkin's lymphoma and cardiac risk factors

    by U. Keilholz, A. Busse, A. Schmittel, G. Hütter, J. Siehl, E. Thiel

    6708 Background: CHOP is the standard combination chemotherapy for high-grade Non-Hodgkin's-lymphoma (NHL). Pegliposomal doxorubicin in comparison to free doxorubicin has minimal cardiotoxicity. We performed a phase I/II study of a modified CHOP regimen including pegliposomal doxorubicin, termed CLAOP, in patients with high-grade NHL and cardiac risk factors. Methods: A three-weekly (CLAOP21) and a bi-weekly (CLAOP14) regimen were explored: CLAOP21 with 20mg/m2 of pegliposomal doxorubicin every 21 days, and a dose-dense CLAOP14 regimen every 14 days with escalating doses of pegliposomal doxorubicin supported by G-CSF. Results: 113 treatment cycles were administered to 22 patients. In the initial 12 patients CLAOP21/20mg/m2 was well tolerated with a degree of hematotoxicity similar to that reported with regular CHOP. The dose-dense CLAOP14/20mg/m2 was not associated with dose-limiting hematotoxicity, but three febrile episodes occurred in 27 treatment cycles. CLAOP14/25mg/m2 was associated with dose-limiting hematotoxicity and palmar plantar erythema. Grade III leucopenia and febrile infections developed in 3 of 5 patients, and PPE grade III in 2 of 5 patients, respectively. Both, the 3-weekly and the 2-weekly regimens were active with an overall response rate of 60%. Cardiotoxicity attributable to doxorubicin was not observed in any patient. Conclusions: The recommended dose of pegliposomal doxorubicin in the CLAOP regimen for Phase II/III testing is 20mg/m2. This regimen can be administered to lymphoma patients with concomitant cardiovascular disease without apparent cardiotoxicity.

  • Ifosfamide for intraocular lymphoma

    by E. Thiel, K. Jahnke, T. Wagner, N. E. Bechrakis, S. E. Coupland, A. Schmittel, L. Fischer, M. H. Foerster, A. Korfel

    1520 Background: Intraocular lymphoma (IOL) occurs as a manifestation of a primary central nervous system lymphoma (PCNSL) or as ocular involvement of a systemic lymphoma. The treatment of IOL has not yet been defined, since the data has been limited to small, usually retrospective treatment series or case reports. CNS relapse is the rule after local treatment modalities. Ifosfamide is administered intravenously (IV) or orally (PO) as the main metabolite of trofosfamide. Its penetration into the eye has never been evaluated but is assumed based on its ability to penetrate the CNS. Methods: We treated 4 patients (pts) with bilateral IOL confirmed by vitrectomy and/or chorioretinal biopsy. Patient (pt) 1, a 83-year-old woman with newly diagnosed primary IOL and multiple comorbidities, refused radiotherapy (RT). Pt 2, a 46-year-old man, had a PCNSL resistant to 3 chemotherapy regimens and relapsed after RT in both eyes. Pt 3, a 77-year-old man, had secondary IOL due to newly diagnosed immunocytoma. Pt 4, a 52-year-old man, had an intraocular relapse of PCNSL after high-dose methotrexate and RT. Pts 1 and 2 received either 150 mg or 400 mg/day of trofosfamide PO on days 1–5 followed by a five-day drug-free interval. Pts 3 and 4 received either 2,000 or 1,500 mg/m2/day of ifosfamide IV days 1–3. Concentrations of ifosfamide and its active metabolite, 4-hydroxy-ifosfamide, were measured in the serum and anterior chamber of the eye in pt 4. Results: According to fundoscopy, pts 1–3 achieved complete remission at 7+, 18 and 3+ months, which was accompanied by a significant increase in visual acuity (VA). Pt 4, who is still under treatment, had a partial remission after one cycle with VA normalization. The 4-hydroxy-ifosfamide concentration in the anterior chamber of the eye was 2.39 μmol/l (54 % of the corresponding serum concentration) directly after the 2-hour infusion. No significant therapy-related side effects were noted in all pts. Conclusions: Ifosfamide seems to be active in IOL with a favorable side effect profile. Trofosfamide can be administered on an outpatient basis. The eye was significantly penetrated by 4-hydroxy-ifosfamide. No significant financial relationships to disclose.

  • Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients

    by A. Schmittel, T. Proebstle, R. Engenhart-Cabillic, C. Scheibenbogen, A.-M. Geueke, E. Thiel, U. Keilholz


  • Application of the IFN-γ ELISPOT assay to quantify T cell responses against proteins

    by Alexander Schmittel, Ulrich Keilholz, Sandra Bauer, Ulrike Kuhne, Stefan Stevanovic, Eckhard Thiel, Carmen Scheibenbogen